Robinul

Drooling, peripheral muscarinic effects, cardiac vagal inhibitory reflexes + 16 more
Treatment
20 Active Studies for Robinul

What is Robinul

GlycopyrroniumThe Generic name of this drug
Treatment SummaryGlycopyrronium is a medication used to treat various conditions and is made up of two enantiomers, which are both quaternary ammonium compounds. It works by blocking signals from the nerves to the muscles, reducing secretions from sweat, oral, airway and gastric glands, and reducing cardiac inhibitory reflexes. It is used to treat peptic ulcers, reduce bronchoconstriction in COPD, and is considered to have a wider therapeutic window than tiotropium. Glycopyrronium was approved by the FDA in 1961 and is one of the most commonly prescribed anticholinergic medications
Robinulis the brand name
Robinul Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Robinul
Glycopyrronium
1961
294

Effectiveness

How Robinul Affects PatientsGlycopyrronium is a medication used to block certain signals of the nervous system. It is effective for a long time and is considered safer than other similar medications. However, patients should be aware of the potential risks, such as worsening urinary retention, overheating, and blurred vision.
How Robinul works in the bodyGlycopyrronium is an anti-muscarinic drug that blocks the M1, M3, M2/M4, and M5 muscarinic receptors. Muscarinic receptors in the lungs are mainly responsible for narrowing airways and producing mucus. They also help control the amount of saliva and sweat produced, as well as the acidity of stomach acid. By blocking the muscarinic receptors, glycopyrronium reduces mucus and saliva production, and decreases the acidity of stomach acid. It also blocks the vagal nerve, which normally slows down your heart rate, which can lead to a slower

When to interrupt dosage

The prescribed dosage of Robinul relies upon the determined condition, for example, Peptic Ulcer, Neurological Conditions and Drooling. The amount of dosage is contingent upon the strategy of delivery (e.g. Capsule - Respiratory (inhalation) or Aerosol, metered) as presented in the table beneath.
Condition
Dosage
Administration
Drooling
, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg
, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Increased upper airway secretion
, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg
, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Induction of anesthesia therapy
, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg
, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Choking
, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg
, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Bronchitis, Chronic
, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg
, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Peptic Ulcer
, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg
, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
General Surgery
, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg
, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Cerebral Palsy
, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg
, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Hyperhidrosis disorder
, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg
, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Oral cavity
, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg
, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Anticholinergic Syndrome
, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg
, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Reflex, Trigeminocardiac
, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg
, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Reflex, Trigeminocardiac
, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg
, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Chronic Obstructive Pulmonary Disease
, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg
, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
peripheral muscarinic effects
, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg
, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
cardiac vagal inhibitory reflexes
, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg
, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Bodily secretions
, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg
, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Emphysema
, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg
, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating
Neurological Conditions
, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg
, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

Warnings

Robinul Contraindications
Condition
Risk Level
Notes
Ulcerative Colitis
Do Not Combine
Uterine Inertia
Do Not Combine
Ulcerative Colitis
Do Not Combine
Myasthenia Gravis
Do Not Combine
Arterial Occlusive Diseases
Do Not Combine
Cardiovascular Physiological Phenomena
Do Not Combine
Pulse Frequency
Do Not Combine
Therapeutic procedure
Do Not Combine
Intestinal Pseudo-Obstruction
Do Not Combine
Open-angle glaucoma
Do Not Combine
Uropathy Obstructive
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Glycopyrronium may interact with Pulse Frequency
There are 20 known major drug interactions with Robinul.
Common Robinul Drug Interactions
Drug Name
Risk Level
Description
Aclidinium
Major
The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Aclidinium.
Cimetropium
Major
The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Cimetropium.
Eluxadoline
Major
The risk or severity of constipation can be increased when Glycopyrronium is combined with Eluxadoline.
Macimorelin
Major
The therapeutic efficacy of Macimorelin can be decreased when used in combination with Glycopyrronium.
Secretin human
Major
The therapeutic efficacy of Secretin human can be decreased when used in combination with Glycopyrronium.
Robinul Toxicity & Overdose RiskTaking too much Atropine can cause flushing, fever, an increased heart rate, difficulty urinating, sensitivity to light, enlarged pupils, nausea, vomiting, dizziness, feeling faint, and constipation. The toxic dose for mice is 570 mg/kg when taken orally, and 709 mg/kg when taken by mouth in rats. When given through an injection in mice, the toxic dose is 90 mg/kg, and 196 mg/kg in rats. Patients should be treated with supportive care such as catheters to manage urinary retention, cardiovascular support, and ventilation, if needed.

Robinul Novel Uses: Which Conditions Have a Clinical Trial Featuring Robinul?

164 active clinical trials are investigating the potential of Robinul to alleviate symptoms of Chronic Obstructive Pulmonary Disease (COPD), cardiac vagal inhibitory reflexes and for use in General Surgery.
Condition
Clinical Trials
Trial Phases
Chronic Obstructive Pulmonary Disease
77 Actively Recruiting
Phase 3, Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 4
Choking
4 Actively Recruiting
Not Applicable
General Surgery
2 Actively Recruiting
Not Applicable
Hyperhidrosis disorder
0 Actively Recruiting
Increased upper airway secretion
0 Actively Recruiting
Anticholinergic Syndrome
0 Actively Recruiting
Induction of anesthesia therapy
0 Actively Recruiting
Reflex, Trigeminocardiac
0 Actively Recruiting
Emphysema
4 Actively Recruiting
Phase 2, Not Applicable
Oral cavity
0 Actively Recruiting
peripheral muscarinic effects
0 Actively Recruiting
Reflex, Trigeminocardiac
0 Actively Recruiting
Drooling
0 Actively Recruiting
Neurological Conditions
1 Actively Recruiting
Not Applicable
Bronchitis, Chronic
0 Actively Recruiting
cardiac vagal inhibitory reflexes
0 Actively Recruiting
Peptic Ulcer
0 Actively Recruiting
Bodily secretions
0 Actively Recruiting
Cerebral Palsy
0 Actively Recruiting

Patient Q&A Section about robinul

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How long does it take Robinul to work?

"Studies have shown that glycopyrrolate is safe and effective in treating hyperhidrosis, with results typically observed within one week."

Answered by AI

What are side effects of Robinul?

", headache, muscle aches, cramps;, itching;, decreased appetite;, increased appetite;

The text lists a number of potential side effects that may occur after taking medication. These include constipation, nausea, vomiting, bloating, drowsiness, dizziness, weakness, feeling nervous, slow heartbeats, sleep problems, blurred vision, sensitivity to light, dry mouth, decreased sense of taste, decreased sweating, decreased urination, impotence, sexual problems, headache, muscle aches, cramps, itching, decreased appetite, and increased appetite."

Answered by AI

What does Robinul do to heart rate?

"ROBINUL works by blocking an enzyme in the nervous system that is responsible for producing saliva in your mouth and secretions in your stomach and lungs. This enzyme also slows down the heart rate. When this enzyme is blocked, secretions dry up and the heart rate increases."

Answered by AI

What is the drug Robinul used for?

"Glycopyrrolate belongs to a class of drugs named anti-cholinergics.

Glycopyrrolate is used in combination with other drugs to treat peptic ulcers, which are a type of stomach or intestinal ulcer. This medication may help relieve pain in the stomach or abdomen. Glycopyrrolate is a type of drug known as an anticholinergic."

Answered by AI

Clinical Trials for Robinul

Image of Stanford University in Stanford, United States.

MoblO2 for Chronic Lung Diseases

18+
All Sexes
Stanford, CA
Many patients with chronic lung disease (e.g., chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD)) require supplemental oxygen (O2) at some point during their disease course. Practitioners prescribe O2 to patients with chronic lung disease in hopes of the following: 1) that it will limit desaturation events and combat breathlessness, thus preventing the frustratingly slow pace and numerous rest breaks patients are forced to adopt while doing even simple tasks; 2) that it will allow patients to be more active physically (perhaps increase their ability to exercise) and socially (perhaps leave the home more often); 3) that it will stave off putative complications of hypoxemia (e.g., cognitive dysfunction, pulmonary hypertension) and 4) that it will improve health-related quality of life (HRQL). However, despite the rationale for O2, and prescribers' good intentions, patients generally view O2 with frustration and fear - it threatens their HRQL, which is already impaired by having a condition that imposes itself on every aspect of their lives. Nasal cannulas and delivery devices call unwanted attention to patients when they are out in public. O2 users feel stigmatized and are often viewed as "smokers who get what they deserve, even if they never smoked a day in their lives" - or as disabled, sick or even infectious. O2 steals patients' independence, forcing them to plan their lives around it. The anxiety that patients and their caregivers experience around running out of oxygen, or not getting enough, immobilizes them and restricts participation in activities outside of the home. O2 disrupts the home environment, adding stress, and creating a burden for patients' caregiver-loved-ones who are often saddled with the responsibility of ensuring adequate equipment and supply of O2, and O2 is a constant reminder to patients they are living with a condition that could shorten their lives. O2 delivery equipment is typically heavy, unwieldy and intimidating. Different recommendations (e.g., insurance companies use 88% as a cut-off for SpO2, while many practitioners focus on 90%) make it confusing for patients, which almost certainly affects adherence. O2-requiringpatients are starving for things that can make their lives easier. An auto-adjusting O2 delivery device - one that automatically delivers the correct amount of O2 to maintain blood oxygen at desired, pre-set levels - would alleviate the need for patients to constantly (incessantly for many) monitor their peripheral oxygen saturation (SpO2) and adjust O2flow to meet the demands as exertion levels vary . The MoblO2 device is a battery-operated, light-weight, closed-loop O2 delivery device that houses a regulator (which attaches to compressed gas O2 tanks) and adjusts O2 flow to meet a pre-set blood oxygen level. A pulse oximeter is worn on the ear and transmits via Bluetooth to the device, which adjusts an internal valve to control flow on a second-to-second basis. The user sets the dial to the highest flow of O2 needed to meet the demands of activities they might perform (up to 15 liters per minute), and the device adjusts flow, up to the pre-set level to maintain SpO2 at a preset level (e.g., \> 90%). To conserve O2 supply in the tank - and to avoid over-oxygenation (which could be problematic for a small percentage of patients with the most severe COPD) - the MoblO2 begins to limit O2 flow at a SpO2 of 93%. The device can be manually over-ridden by the user, and should the battery run out - or the device fail for some unforeseen reason - the default position is valve open, so the users receive whatever flow of oxygen has been set on the dial. Given the substantial burdens of O2 on patients and their families, the hassles patients describe with having to monitor their SpO2 and repeatedly adjust the flow of O2 to meet their needs, patients and experts around the world have called for improvements in O2 delivery equipment. The MoblO2 is just such a remarkable improvement and a giant step forward in helping to ease the burdens of O2 on patients who require it. The purpose of this study is to investigate the effects of the MoblO2 O2 delivery device on a range of outcomes, including physical activity, amount (liters) O2 use; maintenance of adequate SpO2 levels; patient reported outcomes including symptoms, HRQL and satisfaction with the MoblO2 O2 device.
Waitlist Available
Has No Placebo
Stanford UniversityJeff Swigris, DO, MSMinnesota Health Solutions
Have you considered Robinul clinical trials? We made a collection of clinical trials featuring Robinul, we think they might fit your search criteria.Go to Trials
Have you considered Robinul clinical trials? We made a collection of clinical trials featuring Robinul, we think they might fit your search criteria.Go to Trials
Image of Cleveland Clinic Foundation in Cleveland, United States.

Multidisciplinary Clinic Evaluation for Sarcopenia Due to COPD

18+
All Sexes
Cleveland, OH
Sarcopenia, or skeletal muscle loss, impacts up to 40% of COPD patients and is a major cause for morbidity and mortality. Despite the high clinical significance of sarcopenia in COPD, the diagnosis remains elusive because accurate measures of skeletal muscle are not tested during routine clinical care. The goal is to use evidence-based strategies to diagnose and treat sarcopenia due to COPD. The multidisciplinary team includes a pulmonologist, pharmacist, COPD nurse, and COPD coordinator. The investigators anticipate that the approach will improve clinical outcomes for COPD patients with sarcopenia as compared to standard of care visits in ambulatory COPD clinics. The investigators will determine if the approach improves skeletal muscle mass and function, and also improves clinical outcomes related to frequency of hospitalization or ED (Emergency Department) visits, COPD exacerbations, and mortality.
Recruiting
Has No Placebo
Cleveland Clinic FoundationAmy Attaway, MD
Image of Duke Asthma Allergy and Airway Center in Durham, United States.

Inhaled Treprostinil for Chronic Obstructive Pulmonary Disease

18+
All Sexes
Durham, NC
The goal of this clinical trial is to evaluate whether inhaled Treprostinil (Tyvaso) can improve oxygen delivery and blood flow in the lungs in adults (age ≥40) with chronic obstructive pulmonary disease (COPD) and hypoxemia who have less severe reduction in lung blood volume (diffusing capacity of the lungs for carbon monoxide \[DLCO\] ≥45%). The main questions it aims to answer are: 1. Does inhaled Treprostinil increase pulmonary capillary blood volume in ventilated lung regions, as measured by hyperpolarized xenon-129 magnetic resonance imaging (HP129Xe MRI)? 2. Does inhaled Treprostinil improve oxygen delivery (measured as red blood cell \[RBC\] chemical shift) and maintain or only slightly change pulmonary vascular resistance (measured by RBC oscillation amplitude)? 3. Can pre-treatment MRI parameters (RBC transfer and RBC oscillation amplitude) predict who will respond to inhaled Treprostinil? Participants will: * Use the Tyvaso nebulizer (inhaled Treprostinil) 4 times daily for 4 weeks, starting at 3 breaths per session and increasing to a maximum of 6 breaths per session as tolerated. * Undergo HP129Xe MRI before and after treatment to assess regional lung function and oxygen exchange. * Complete pulmonary function tests (PFTs), 6-minute walk tests (6MWT), and echocardiograms at the beginning and end of the study. * Be monitored for adverse events, with a phone check-in midway through and after the treatment period.
Phase 2
Recruiting
Duke Asthma Allergy and Airway CenterUnited Therapeutics
Image of Duke University Hospital in Durham, United States.

Photon-counting CT for Chronic Obstructive Pulmonary Disease

Any Age
All Sexes
Durham, NC
Purpose and objective: This project aims to evaluate photon-counting computed tomography (PCCT) quantitative accuracy using COPDGene subjects. The goal is to establish acquisition protocols for PCCT scans with proper post-processing (e.g., reconstruction parameters and harmonization techniques) that enable reproducible measurements of emphysema metrics (e.g., Perc15, LAA-950, HU accuracy) and airways (Pi10, WA%) in the lungs. Study activities and population group: The study will recruit subjects from a current study at Duke (COPDGene Phase 4, Pro00113442). Here are the aims: * The research team will request consent from participants to acquire PCCT scans at their Phase 4 COPDGene visit. Scans will be performed using a PCCT-specific protocol. * Reconstruct the PCCT images with multiple post-acquisition parameter settings. Apply harmonization techniques that are recently developed by the investigators of this study. Data analysis: * Identify the reconstruction and harmonization conditions that enable reproducible measurements of emphysema metrics (perc15, LAA-950, HU accuracy) and airways (Pi10, WA%), when compared to the counterpart EICT scans. * Demonstrate the non-inferiority and potentially improved capabilities of PCCT scans in cross-sectional and longitudinal studies. Risk/safety issues: The participants are asked to get an additional CT scan with a PCCT scanner at their COPDGene Phase 4 visit. This additional CT scan will be done using an inspiratory chest protocol with a total of 3 mGy (\~1.5 mSv) radiation dose. This is roughly equivalent of 6 month of background radiation. Women who are pregnant will not have a chest CT scan done until they are confirmed to be not pregnant.
Recruiting
Has No Placebo
Duke University HospitalEhsan Abadi, Ph.D.
Have you considered Robinul clinical trials? We made a collection of clinical trials featuring Robinul, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security